Kinase inhibitors as potential agents in the treatment of multiple myeloma.

摘要: // Hanley N. Abramson 1 Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA Correspondence to: Abramson, email: Keywords : multiple myeloma, kinase inhibitors Received March 04, 2016 Accepted June 30, Published July 20, Abstract Recent years have witnessed a dramatic increase in the number therapeutic options available for treatment myeloma (MM) - from immunomodulating agents to proteasome histone deacetylase (HDAC) and, most recently, monoclonal antibodies. Used conjunction with autologous hematopoietic stem cell transplantation, these modalities nearly doubled disease’s five-year survival rate over last three decades about 50%. In spite advances, MM still is considered incurable as resistance and relapse are common. While small molecule protein made inroads therapy cancers, date their application has been less than successful. Focusing on MM, this review examines roles played by kinases driving malignant state rationale target development design that demonstrated anti-myeloma activity both vitro vivo xenograph models, well those entered clinical trials. Among targets examined receptor non-receptor tyrosine kinases, cycle control PI3K/AKT/mTOR pathway C, mitogen-activated kinase, glycogen synthase casein integrin-linked sphingosine involved unfolded response.